Pure Em Life Science India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 06-07-2024
- Paid Up Capital ₹ 0.15 M
as on 06-07-2024
- Company Age 5 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 84.73%
(FY 2023)
- Profit 33.34%
(FY 2023)
- Ebitda 62.62%
(FY 2023)
- Net Worth 252.14%
(FY 2023)
- Total Assets 70.07%
(FY 2023)
About Pure Em Life Science India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.15 M, as per Ministry of Corporate Affairs (MCA) records.
Fazil Salam, Joe Mampilly, Sam Babu, and One other member serve as directors at the Company.
- CIN/LLPIN
U33309KL2019PTC058947
- Company No.
058947
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jul 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Pure Em Life Science India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Fazil Salam  | Managing Director | 24-Jul-2019 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Joe Mampilly | Director | 01-Apr-2022 | Current |
| Geemon Korah | Director | 01-Apr-2022 | Current |
| Sam Babu | Director | 24-Jul-2019 | Current |
Financial Performance of Pure Em Life Science India.
Pure Em Life Science India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 84.73% increase. The company also saw a substantial improvement in profitability, with a 33.34% increase in profit. The company's net worth Soared by an impressive increase of 252.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pure Em Life Science India?
In 2023, Pure Em Life Science India had a promoter holding of 66.66% and a public holding of 33.34%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Pure Em Life Science India?
Unlock and access historical data on people associated with Pure Em Life Science India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pure Em Life Science India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pure Em Life Science India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
